173 related articles for article (PubMed ID: 35502108)
41. Impending Central Retinal Vein Occlusion in a Patient with Coronavirus Disease 2019 (COVID-19).
Invernizzi A; Pellegrini M; Messenio D; Cereda M; Olivieri P; Brambilla AM; Staurenghi G
Ocul Immunol Inflamm; 2020 Nov; 28(8):1290-1292. PubMed ID: 32976055
[TBL] [Abstract][Full Text] [Related]
42. Risk of New Retinal Vascular Occlusion After Messenger RNA COVID-19 Vaccination Within Aggregated Electronic Health Record Data.
Chen YC; Chen CC; Wei JC
JAMA Ophthalmol; 2023 Dec; 141(12):1177. PubMed ID: 37943564
[No Abstract] [Full Text] [Related]
43. Risk of New Retinal Vascular Occlusion After Messenger RNA COVID-19 Vaccination Within Aggregated Electronic Health Record Data.
Chu PJ; Tai TH; Fan TH
JAMA Ophthalmol; 2023 Dec; 141(12):1176-1177. PubMed ID: 37943546
[No Abstract] [Full Text] [Related]
44. Risk of New Retinal Vascular Occlusion After Messenger RNA COVID-19 Vaccination Within Aggregated Electronic Health Record Data.
Hsu AY; Lin CJ; Wei JC
JAMA Ophthalmol; 2023 Dec; 141(12):1175-1176. PubMed ID: 37943534
[No Abstract] [Full Text] [Related]
45. Central retinal vein occlusion secondary to varicella zoster retinal vasculitis in an immunocompetent individual during the COVID-19 pandemic - A case report.
Sarpangala S; George NM; Kamath YS; Kulkarni C
Indian J Ophthalmol; 2021 Sep; 69(9):2532-2535. PubMed ID: 34427261
[TBL] [Abstract][Full Text] [Related]
46. Prevalence of SARS-CoV-2 among central retinal vein occlusion patients.
Sunny ; Au CL
Indian J Ophthalmol; 2021 May; 69(5):1355-1356. PubMed ID: 33913913
[No Abstract] [Full Text] [Related]
47. BNT162b2 mRNA SARS-CoV-2 vaccination does not cause upregulation of endothelial activation markers or hypercoagulability: A prospective, single-arm, longitudinal study.
Lim XR; Leung BP; Sum CLL; Lim GH; Chua CG; Tu TM; Ramanathan K; Huang MY; Howe HS; Fan BE
Am J Hematol; 2022 Apr; 97(4):E141-E144. PubMed ID: 35015303
[No Abstract] [Full Text] [Related]
48. Equivalent humoral and cellular immune response but different side effect rates following SARS-CoV-2 vaccination in peritoneal and haemodialysis patients using messenger RNA vaccines.
Stumpf J; Klimova A; Mauer R; Steglich A; Gembardt F; Martin H; Glombig G; Frank K; Tonn T; Hugo C
Nephrol Dial Transplant; 2022 Mar; 37(4):796-798. PubMed ID: 34791446
[No Abstract] [Full Text] [Related]
49. Incidence of Cerebral Venous Thrombosis Following SARS-CoV-2 Infection vs mRNA SARS-CoV-2 Vaccination in Singapore.
Tu TM; Yi SJ; Koh JS; Saffari SE; Hoe RHM; Chen GJ; Chiew HJ; Tham CH; Seet CYH; Yong MH; Yong KP; Hui AC; Fan BE; Tan BY; Quek AML; Seet RCS; Yeo LLL; Tan K; Thirugnanam UN
JAMA Netw Open; 2022 Mar; 5(3):e222940. PubMed ID: 35297971
[TBL] [Abstract][Full Text] [Related]
50. Neuralgic amyotrophy following COVID-19 mRNA vaccination.
Koh JS; Goh Y; Tan BY; Hui AC; Hoe RHM; Makmur A; Kei PL; Vijayan J; Ng KWP; Quek AML; Thirugnanm U
QJM; 2021 Nov; 114(7):503-505. PubMed ID: 34347105
[No Abstract] [Full Text] [Related]
51. COVID-19 vaccination in a cancerous patient: A comment.
Mungmungpuntipantip R; Wiwanitkit V
J Cancer Res Ther; 2021; 17(6):1587. PubMed ID: 34916404
[No Abstract] [Full Text] [Related]
52. Myocarditis After BNT162b2 and mRNA-1273 Vaccination.
Larson KF; Ammirati E; Adler ED; Cooper LT; Hong KN; Saponara G; Couri D; Cereda A; Procopio A; Cavalotti C; Oliva F; Sanna T; Ciconte VA; Onyango G; Holmes DR; Borgeson DD
Circulation; 2021 Aug; 144(6):506-508. PubMed ID: 34133884
[TBL] [Abstract][Full Text] [Related]
53. Oncologist counseling practice and COVID-19 vaccination outcomes for patients with history of PEG-asparaginase hypersensitivity.
Zarnegar-Lumley S; Stone CA; Smith CM; Hall LL; Luck KE; Koo G; Plager JH; Phillips EJ; Friedman DL
Pediatr Blood Cancer; 2022 Jul; 69(7):e29686. PubMed ID: 35353440
[TBL] [Abstract][Full Text] [Related]
54. Arthritis of the left elbow joint after vaccination against SARS-CoV-2 infection.
Baimukhamedov C
Int J Rheum Dis; 2021 Sep; 24(9):1218-1220. PubMed ID: 34363344
[No Abstract] [Full Text] [Related]
55. Anti-SARS-CoV-2 mRNA vaccines as inducers of humoral response against apolipoprotein A-1?
Vuilleumier N; Pagano S; Ludewig B; Schmiedeberg K; Haller C; von Kempis J; Rubbert-Roth A
Eur J Clin Invest; 2022 Feb; 52(2):e13713. PubMed ID: 34841527
[TBL] [Abstract][Full Text] [Related]
56. Successful mRNA SARS-Cov-2 vaccine rechallenge after a first episode of immune thrombocytopenic purpura.
Chanut M; Jaidi R; Kohn M; Grange T; Brones C; Lombion N; Rousselot P; Longval T
Platelets; 2022 May; 33(4):652-653. PubMed ID: 35225144
[TBL] [Abstract][Full Text] [Related]
57. Safety of mRNA-based vaccines against SARS-CoV-2 in people with cystic fibrosis aged 12 years and over.
Alicandro G; Daccó V; Cariani L; Contarini M; Morlacchi LC; Rosazza C; Sciarrabba CS; Ferraro F; Lanfranchi C; Orena BS; Gramegna A; Blasi F; Colombo C
J Cyst Fibros; 2022 May; 21(3):e173-e175. PubMed ID: 35256306
[No Abstract] [Full Text] [Related]
58. Stroke after SARS-CoV-2 vaccination: Comment.
Kleebayoon A; Mungmunpuntipantip R; Wiwanitkit V
Clinics (Sao Paulo); 2023; 78():100246. PubMed ID: 37454535
[No Abstract] [Full Text] [Related]
59. Does mRNA SARS-CoV-2 vaccine influence patients' performance during IVF-ET cycle?
Orvieto R; Noach-Hirsh M; Segev-Zahav A; Haas J; Nahum R; Aizer A
Reprod Biol Endocrinol; 2021 May; 19(1):69. PubMed ID: 33985514
[TBL] [Abstract][Full Text] [Related]
60. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial.
Bonelli M; Mrak D; Tobudic S; Sieghart D; Koblischke M; Mandl P; Kornek B; Simader E; Radner H; Perkmann T; Haslacher H; Mayer M; Hofer P; Redlich K; Husar-Memmer E; Fritsch-Stork R; Thalhammer R; Stiasny K; Winkler S; Smolen JS; Aberle JH; Zeitlinger M; Heinz LX; Aletaha D
Ann Rheum Dis; 2022 May; 81(5):687-694. PubMed ID: 35027397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
